Status Awaiting development
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process STA Standard
ID number 6288

Provisional Schedule

Committee meeting 04 August 2024
Expected publication 13 November 2024

Project Team

Project lead

Email enquiries


Companies sponsors Eli Lilly (selpercatinib)
Others Department of Health and Social Care
  NHS England
Patient carer groups Association for Multiple Endocrine Neoplasia Disorders (AMEND)
  Black Health Agency for Equality
  British Thyroid Foundation
  Butterfly Thyroid Cancer Trust
  Cancer Black Care
  Cancer Equality
  Helen Rollason Cancer Charity
  Independent Cancer Patients Voice
  Macmillan Cancer Support
  Maggie’s Centres
  Marie Curie
  South Asian Health Foundation
  Specialised Healthcare Alliance
  Tenovus Cancer Care
  Thyroid Cancer Support Group Wales
  Thyroid UK
Professional groups Association of Cancer Physicians
  Association of Surgeons of Great Britain & Ireland
  British Association of Endocrine and Thyroid Surgeons
  British Association of Surgical Oncology
  British Geriatrics Society
  British Institute of Radiology
  British Psychosocial Oncology Society
  British Thyroid Association
  Cancer Research UK
  Health Lumen
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Radiologists
  Royal College of Surgeons
  Royal Pharmaceutical Society
  Royal Society of Medicine
  Society and College of Radiographers
  Society for Endocrinology
  Thyroid Cancer Forum-UK
  UK Clinical Pharmacy Association
  UK Oncology Nursing Society
Associated public health groups Public Health Wales
  UK Health Security Agency
Comparator companies None
General commentators All Wales Therapeutics and Toxicology Centre
  Allied Health Professionals Federation
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  National Association for Primary Care
  National Pharmacy Association
  NHS Alliance
  NHS Confederation
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
  Welsh Government
Relevant research groups Cochrane UK
  Genomics England
  Institute of Cancer Research
  MRC Clinical Trials Unit
  National Institute for Health Research
  Pro-Cancer Research Fund


Key events during the development of the guidance:

Date Update
05 February 2024 Invitation to participate
05 December 2023 - 16 January 2024 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
05 December 2023 Awaiting development. Status change linked to Topic Selection Decision being set to Selected
05 December 2023 NICE will be undertaking a guidance update for [TA742] Selpercatinib for treating advanced thyroid cancer with RET alterations which recommended the use of Selpercatinib in the Cancer Drugs Fund while further data were collected. The aim of the update is to decide whether or not the drug can be recommended for routine use after data collection is complete. Please see draft timelines we have planned for your information. Following conversations with the company the appraisal is expected to start in approximately early December 2023 with a consultation on the draft scope. It is then anticipated that the final scope will be released along with an Invitation to Participate in the appraisal during early February 2024 when we will write to you about how you can get involved.

For further information on our processes and methods, please see our CHTE processes and methods manual